Cargando…
Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma
BACKGROUND: Proteasome inhibitors (PI) bortezomib and carfilzomib are cornerstone therapies for multiple myeloma. Higher incidence of cardiac adverse events (CAEs) has been reported in patients receiving carfilzomib. However, risk factors for cardiac toxicity remain unclear. Our objective was to eva...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048104/ https://www.ncbi.nlm.nih.gov/pubmed/32154000 http://dx.doi.org/10.1186/s40959-017-0023-9 |